Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
5
×
deals
life sciences
national blog main
startups
5
×
san francisco blog main
san francisco top stories
boston blog main
fda
national top stories
san diego blog main
san diego top stories
san francisco
boston top stories
food and drug administration
ipo
new york blog main
new york top stories
raleigh-durham blog main
abbvie
acetylon pharmaceuticals
akouos
allergan
alnylam pharmaceuticals
amag pharmaceuticals
ambys medicines
amunix
anirvan ghosh
astrazeneca
atrial fibrillation
biogen
bluerock therapeutics
boston
boston scientific
boulder/denver blog main
boulder/denver top stories
cancer
cancer immunotherapy
cell therapy
cerovene
What
deal
5
×
acquire
bio
business
medicines
startup
ability
acquisitions
adding
aiming
ambys
announced
array
atrial
babies
big
biotech
boston
building
ceo
collabs
continues
control
cost
covid
cryterion
daniel
deadly
debuted
developer
device
disease
diseases
drug
established
expand
fibrillation
firm
formed
future
Language
unset
Current search:
deal
×
biotech
×
startups
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Invitae Offers $55M for Singular Bio to Expand Prenatal Test Business
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
Boston Scientific Continues M&A Streak with $202M Deal for Cryterion
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed
